AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR 120.50
-1.00 (-0.82%)
Jun 25, 2025, 3:41 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B USD in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.69
Revenue / Employee
$583.05K
Employees
94,300
Market Cap
187.73B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius SE & Co. KGaA | 22.13B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
AstraZeneca News
- 1 day ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 1 day ago - AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. - WSJ
- 1 day ago - US approves AstraZeneca, Daiichi's treatment for lung cancer - Reuters
- 1 day ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 4 days ago - Is the Market Bullish or Bearish on AstraZeneca? - Benzinga
- 8 days ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 11 days ago - 5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List - Seeking Alpha
- 11 days ago - AstraZeneca in deal with China firm worth up to £4bn - This is Money